Aptose Biosciences Inc. has received a positive endorsement from Glass Lewis & Co., a leading independent proxy advisory firm, regarding its proposed plan of arrangement with Hanmi Pharmaceutical Co. Ltd. Shareholders are advised to vote 'FOR' the special resolution to approve the arrangement, which involves the acquisition of all outstanding common shares of Aptose not currently owned by Hanmi or its affiliates. This recommendation comes as Aptose prepares for a special meeting of shareholders, which has been rescheduled to March 31, 2026. The meeting aims to secure approval for both the arrangement and a continuance that will transition the company from being governed under the Canada Business Corporations Act to the Business Corporations Act (Alberta). The completion of this transaction is contingent upon customary closing conditions, including court approval and the approval of the Toronto Stock Exchange (TSX). Shareholders are reminded of the proxy voting deadline set for March 27, 2026, and are encouraged to submit their votes promptly to ensure representation at the meeting. The board of directors of Aptose has unanimously recommended that shareholders support the resolutions, highlighting the strategic benefits of the arrangement with Hanmi, which is expected to enhance Aptose's operational capabilities and market position in the oncology sector. As a clinical-stage biotechnology company, Aptose is focused on developing precision medicines to address unmet medical needs in oncology, particularly in hematology. The lead clinical-stage compound, TUS, is an oral kinase inhibitor that has shown promise in treating patients with relapsed or refractory acute myeloid leukemia (AML). This endorsement from Glass Lewis is seen as a significant step forward for Aptose as it navigates this critical phase in its growth and development.

Press Release distribution

National Press Distribution across U.S. Media. Direct Access to Key Decision Making Editors.